Eiger BioPharmaceuticals to Host and Webcast Virtual Key Opinion Leader Event on Hepatitis Delta Virus Monday, November 15
Presenting Key Opinion Leaders:
- Pietro Lampertico, MD, PhD: Professor of Gastroenterology, Director of the Gastroenterology and Hepatology Division, and Head of the "A. M. e A. Migliavacca"
Center for Liver Diseaseat the Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, University of Milan, Italy Norah Terrault, MD, MPH: Professor of Medicine and Chief of Gastroenterology and Liver Diseases at the Keck School of Medicineat University of Southern California Ohad Etzion, MD: Assistant Professor, Faculty of Health Sciences, Ben-Gurion Universityof the Negev; Director, Department of Gastroenterology and Liver Diseases, Soroka University Medical Center, Israel
Members of the
The live and replayed webcast of the event will be available through the Investor Relations "Events & Presentations" section of the company's website at www.eigerbio.com. To participate in the event by phone, dial (844) 743-2495 (
About the Presenting Key Opinion Leaders
Dr. Pietro Lampertico has focused his research on the treatment of patients with chronic hepatitis/cirrhosis due to HBV, the long-term outcome of cirrhotic patients undergoing antiviral treatment, and the diagnosis and management of antiviral resistance to oral nucleos(t)ide analogues. Since
About Hepatitis Delta Virus (HDV)
HDV is the most severe form of human viral hepatitis. HDV occurs only as a co-infection in individuals infected with hepatitis B virus (HBV). HDV leads to more severe liver disease than HBV alone and is associated with accelerated liver fibrosis, liver cancer, and liver failure. It is estimated that 60% of HDV infected patients die within ten years. Approved nucleos(t)ide treatments for HBV only suppress HBV DNA, do not affect HBsAg and have no impact on HDV.
HDV is a disease with a significant impact on global health, which may affect up to 15-20 million people worldwide. Globally, HDV infection is reported to be present in approximately 4% to 6% of patients with chronic HBV.
Eiger is a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases.
For additional information about Eiger and its clinical programs, please visit www.eigerbio.com.
Investors and Media:
Sri Ryali – CFO
Email: [email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/eiger-biopharmaceuticals-to-host-and-webcast-virtual-key-opinion-leader-event-on-hepatitis-delta-virus-monday-november-15-301414494.html